138 related articles for article (PubMed ID: 11588518)
1. Inhibition of HIV replication by A77 1726, the active metabolite of leflunomide, in combination with pyrimidine nucleoside reverse transcriptase inhibitors.
Hossain MM; Margolis DM
J Acquir Immune Defic Syndr; 2001 Oct; 28(2):199-201. PubMed ID: 11588518
[No Abstract] [Full Text] [Related]
2. Modulation of human peripheral blood mononuclear cell activation by the combination of leflunomide and pentoxifylline.
Stojic Vukanic Z; Dimitrijevic M; Colic M; Popovic P; Jandric D
Transplant Proc; 2001 May; 33(3):2137-8. PubMed ID: 11377478
[No Abstract] [Full Text] [Related]
3. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.
Cao WW; Kao PN; Chao AC; Gardner P; Ng J; Morris RE
J Heart Lung Transplant; 1995; 14(6 Pt 1):1016-30. PubMed ID: 8719445
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
Greene S; Watanabe K; Braatz-Trulson J; Lou L
Biochem Pharmacol; 1995 Sep; 50(6):861-7. PubMed ID: 7575649
[TBL] [Abstract][Full Text] [Related]
5. Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography.
Dias VC; Lucien J; LeGatt DF; Yatscoff RW
Ther Drug Monit; 1995 Feb; 17(1):84-8. PubMed ID: 7725383
[TBL] [Abstract][Full Text] [Related]
6. Differential modulation of pro- and anti-inflammatory cytokine receptors by N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxy-crotonic acid amide (A77 1726), the physiologically active metabolite of the novel immunomodulator leflunomide.
Mirmohammadsadegh A; Homey B; Abts HF; Köhrer K; Ruzicka T; Michel G
Biochem Pharmacol; 1998 May; 55(9):1523-9. PubMed ID: 10076546
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide.
Mattar T; Kochhar K; Bartlett R; Bremer EG; Finnegan A
FEBS Lett; 1993 Nov; 334(2):161-4. PubMed ID: 8224241
[TBL] [Abstract][Full Text] [Related]
8. In vivo lymphoproliferation in the popliteal lymph node (PLN) assay can be inhibited by leflunomide's active metabolite A77 1726.
Schorlemmer HU; Kurrle R; Schleyerbach R; Bartlett RR
Inflamm Res; 1999 Dec; 48 Suppl 2():S111-2. PubMed ID: 10667839
[No Abstract] [Full Text] [Related]
9. In vitro effects of the active metabolite of leflunomide, A77 1726, on feline herpesvirus-1.
Williams CR; Sykes JE; Mehl M; MacLeod JS; Lindsay LL; Poland AM; Chen YJ; Kyles AE; Waldman WJ; Gregory CR
Am J Vet Res; 2007 Sep; 68(9):1010-5. PubMed ID: 17764417
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.
Manna SK; Aggarwal BB
J Immunol; 1999 Feb; 162(4):2095-102. PubMed ID: 9973483
[TBL] [Abstract][Full Text] [Related]
11. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression.
Chong AS; Huang W; Liu W; Luo J; Shen J; Xu W; Ma L; Blinder L; Xiao F; Xu X; Clardy C; Foster P; Williams JA
Transplantation; 1999 Jul; 68(1):100-9. PubMed ID: 10428276
[TBL] [Abstract][Full Text] [Related]
12. A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases.
Wang J; Sun J; Hu J; Wang C; Prinz RA; Peng D; Liu X; Xu X
FASEB J; 2020 Aug; 34(8):10132-10145. PubMed ID: 32598086
[TBL] [Abstract][Full Text] [Related]
13. The active metabolite of leflunomide, A77 1726, protects rat hepatocytes against bile acid-induced apoptosis.
Vrenken TE; Buist-Homan M; Kalsbeek AJ; Faber KN; Moshage H
J Hepatol; 2008 Nov; 49(5):799-809. PubMed ID: 18809221
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous determination of leflunomide and its active metabolite, A77 1726, in human plasma by high-performance liquid chromatography.
Schmidt A; Schwind B; Gillich M; Brune K; Hinz B
Biomed Chromatogr; 2003 Jun; 17(4):276-81. PubMed ID: 12833393
[TBL] [Abstract][Full Text] [Related]
15. The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1beta and TNF-alpha.
Magne D; Mézin F; Palmer G; Guerne PA
Inflamm Res; 2006 Nov; 55(11):469-75. PubMed ID: 17122964
[TBL] [Abstract][Full Text] [Related]
16. Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers.
Zielinski T; Müller HJ; Bartlett RR
Agents Actions; 1993; 38 Spec No():C80-2. PubMed ID: 8317329
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle regulation and inhibition of de novo pyrimidine biosynthesis by leflunomide.
Schorlemmer HU; Milbert U; Zeitter D; Haun G; Wunschel M; Bartlett RR
Inflamm Res; 1999 Dec; 48 Suppl 2():S115-6. PubMed ID: 10667841
[No Abstract] [Full Text] [Related]
18. Leflunomide and malononitrilamides.
Silva Júnior HT; Morris RE
Am J Med Sci; 1997 May; 313(5):289-301. PubMed ID: 9145039
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms.
Miljkovic Dj; Samardzic T; Drakulic D; Stosic-Grujicic S; Trajkovic V
Cytokine; 2002 Aug; 19(4):181-6. PubMed ID: 12297111
[TBL] [Abstract][Full Text] [Related]
20. Single- and multiple-dose pharmacokinetics and pharmacodynamics of leflunomide's active metabolite A77 1726 in normal Lewis rats.
Silva HT; Shorthouse R; Morris RE
Transplant Proc; 1996 Dec; 28(6):3092-4. PubMed ID: 8962197
[No Abstract] [Full Text] [Related]
[Next] [New Search]